TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor * Advanced and/or metastatic disease * Unresponsive to conventional therapy (i.e., disease progressed while receiving any known standard curative or palliative therapy) OR previously untreated tumor for which no standard treatment exists * Measurable or evaluable metastatic disease * No lymphoma or other hematologic malignancy * No known brain metastases * Previously treated brain metastases with no evidence of recurrence allowed PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 3 months * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Creatinine ≤ 2.0 mg/dL * Bilirubin ≤ 2.5 mg/dL * ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases are present) * Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN if liver metastases are present) * Prothrombin time ≤ 1.5 times ULN * Hemoglobin ≥ 10.0 g/dL (transfusion allowed) * LVEF ≥ 45% by echocardiogram or thallium stress test for patients \> 50 years of age or history of cardiovascular disease * FEV\_1 and DLCO \> 30% of predicted for patients with a history of pulmonary disease * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No active bacterial or viral infection with systemic manifestations (e.g., fever, symptoms, leukocytosis) * Localized chronic infections, such as mild acne or tinea pedis allowed * No acute or chronic viral hepatitis * No known bleeding disorder * No other concurrent life-threatening illness, including any of the following: * Unstable angina * Severe oxygen-dependent chronic obstructive pulmonary disease * End-stage liver disease * No known active renal disease or renal insufficiency as evidenced by serum creatinine \> 2.0 mg/dL * No HIV positivity PRIOR CONCURRENT THERAPY: * Recovered from prior therapy * More than 3 weeks since prior biological or cytotoxic agents (6 weeks for nitrosoureas) * No known requirment for palliative treatment * No concurrent surgery * No other concurrent anticancer therapy